Boston, MA -- (SBWIRE) -- 08/02/2012 -- BMI View: The period 2011-16 is forecast to witness the proliferation of government initiatives supporting the growth of Switzerland's generic medicines market, which will increasingly attract prominent international players in the field, as well as prompt local companies to get more involved in the segment. According to data published by Swissmedic, Sandoz Pharmaceuticals, Novartis's generic medicines arm, has 556 preparations locally approved, while Teva has 345 preparations locally approved. However, the implementation of further price controls on the already low-value medicines sector means that drugmakers will find it difficult to maintain suitable levels of sales and profits.

Headline Expenditure Projections

- Pharmaceuticals: CHF6.77bn (US$7.63bn) in 2011 to CHF6.58bn (US$7.00bn) in 2012; -2.8% decline in local currency terms and -8.2% in US dollar terms.
- Healthcare: CHF65.30bn (US$73.6bn) in 2011 to CHF67.42bn (US$71.72bn) in 2012; +3.2% growth in local currency terms and -2.6% in US dollar terms.
- Medical devices: CHF4.77bn (US$5.38bn) in 2011 to CHF4.76bn (US$5.06bn) in 2012; -0.3% growth in local currency terms and -5.8% in US dollar terms.

View Full Report Details and Table of Contents

Risk/Reward Ratings: In BMI's risk/reward ratings (RRRs) for Western Europe in Q312, Switzerland has maintained its position as the top market in the Western Europe matrix, above the UK and France. Switzerland's score for the quarter stands at 70.9, well above the regional average of 65.5. However, BMI anticipates that Switzerland may slip down the world rankings in the medium- to long-term as large, highgrowth emerging markets such as Brazil and China become more alluring to multinational drugmakers.

Key trends and developments in the sector include:

- A study by Santesuisse in early 2012, assessing the prices of medicines in the country, concluded that the Swiss ex-factory prices of off-patented original brand medicines were higher than that in France, the UK, Austria and the Netherlands, but they were lower than in Denmark and Germany. Furthermore, the Swiss ex-factory price of generic medicines was higher than in the entire six reference basket of countries. We note that the analysis was based on MAT/09/2011 volumes and prices at September 2011 and did not include discounts or rebates to pharmacists and payers.
- Multinational drugmaker Novartis posted a 2% decline in net sales in US dollar terms (-1% in constant currency terms) to US$13.74bn for Q112, compared with sales of US$14.03bn in Q111. The strength of the US dollar against most major currencies negatively affected sales by 1%.

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Healthcare research reports at Fast Market Research

You may also be interested in these related reports:

- Egypt Pharmaceuticals & Healthcare Report Q3 2012
- Taiwan Pharmaceuticals & Healthcare Report Q3 2012
- Romania Pharmaceuticals & Healthcare Report Q3 2012
- Cipher Pharmaceuticals Inc. (DND) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- Turkey Pharmaceuticals & Healthcare Report Q3 2012
- Zimbabwe Pharmaceuticals & Healthcare Report Q3 2012
- Oman Pharmaceuticals & Healthcare Report Q3 2012
- Nigeria Pharmaceuticals & Healthcare Report Q3 2012
- Canada Pharmaceuticals & Healthcare Report Q3 2012
- Peru Pharmaceuticals & Healthcare Report Q3 2012